Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues

Novo Nordisk logo

Novo Nordisk

Status

Completed

Conditions

Diabetes Mellitus, Type 1
Diabetes

Treatments

Drug: insulin aspart
Drug: insulin detemir

Study type

Observational

Funder types

Industry

Identifiers

NCT00873639
INS-3721

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoRapid® (insulin aspart) and Levemir® (insulin detemir) after switch from human insulins for treatment of type 1 diabetes under normal clinical practice conditions in Romania.

Enrollment

417 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Any subject with type 1 diabetes who is treated with human rapid and intermediate (NPH) insulin in basal-bolus regimen

Exclusion criteria

  • Subjects currently being treated with insulin aspart and insulin detemir
  • Subjects who were previously enrolled in this study
  • Subjects with a hypersensitivity to insulin aspart or to any of the excipients
  • Subjects with a hypersensitivity to insulin detemir or to any of the excipients
  • Women who are pregnant or have the intention of becoming pregnant within next 6 months

Trial design

417 participants in 1 patient group

A
Treatment:
Drug: insulin detemir
Drug: insulin aspart

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems